Amgen — Oct 30, 2024 release

$Billions, except shares Q3 ’24 Q3 ’23 YOY Δ Operating Cash Flow $ 3.6  $ 2.8  $ 0.8  Capital Expenditures $ 0.3  $ 0.2  $ 0.0  Free Cash Flow $ 3.3  $ 2.5  $ 0.8  Dividends Paid $ 1.2  $ 1.1  $ 0.1  Share Repurchases $ 0.0  $ —  $ 0.0  Average Diluted Shares (millions) 542  538  4  Note: Numbers may not add due to rounding $Billions 9/30/24 12/31/23 YTD Δ Cash and Investments $ 9.0  $ 10.9  $ (1.9) Debt Outstanding $ 60.4  $ 64.6  $ (4.2) Note: Numbers may not add due to rounding AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Page 7 2024 Guidance For the full year 2024, the Company now expects: • Total revenues in the range of $33.0 billion to $33.8 billion. • On a GAAP basis, EPS in the range of $8.71 to $9.56, and a tax rate in the range of 9.0% to 10.5%. • On a non-GAAP basis, EPS in the range of $19.20 to $20.00, and a tax rate in the range of 14.0% to 15.0%. • Capital expenditures to be approximately $1.3 billion. • Share repurchases not to exceed $500 million. Third Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a multispecific molecule that inhibits the gastric inhibitory polypeptide receptor (GIPR) and activates the glucagon like peptide 1 (GLP-1) receptor. • A Phase 2 study of MariTide is ongoing in adults who are living with overweight or obesity, with or without Type 2 diabetes mellitus. Topline data are anticipated in late 2024. • Planning for a broad Phase 3 program across multiple indications remains on track. • A Phase 2 study investigating MariTide was initiated for the treatment of Type 2 diabetes in patients with and without obesity. AMG 513 • A Phase 1 study of AMG 513 was initiated and is enrolling patients living with obesity. Olpasiran (AMG 890) • Olpasiran is a po